Top-Rated StocksTop-RatedTop MarketRank™ StocksTop MarketRank™NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $20.03 +0.05 (+0.25%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$19.94▼$20.5850-Day Range$19.37▼$30.9052-Week Range$19.34▼$40.16Volume973,328 shsAverage Volume760,141 shsMarket Capitalization$932.40 millionP/E Ratio14.01Dividend YieldN/APrice Target$43.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pacira BioSciences alerts: Email Address Pacira BioSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside117.7% Upside$43.60 Price TargetShort InterestBearish13.96% of Shares Sold ShortDividend StrengthN/ASustainability-1.89Upright™ Environmental ScoreNews Sentiment0.56Based on 6 Articles This WeekInsider TradingSelling Shares$602,170 Sold Last QuarterProj. Earnings Growth34.27%From $2.13 to $2.86 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.94 out of 5 starsMedical Sector16th out of 936 stocksPharmaceutical Preparations Industry4th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePacira BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.96% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 3.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.89. Previous Next 3.1 News and Social Media Coverage News SentimentPacira BioSciences has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.Search Interest8 people have searched for PCRX on MarketBeat in the last 30 days. MarketBeat Follows9 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $602,170.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 34.27% in the coming year, from $2.13 to $2.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 14.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 14.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Pacira BioSciences Stock (NASDAQ:PCRX)Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More PCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCRX Stock News HeadlinesJuly 4, 2024 | insidertrades.comJonathan Slonin Sells 2,836 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockJuly 23 at 7:16 AM | americanbankingnews.comReviewing Pacira BioSciences (NASDAQ:PCRX) & Nanobiotix (NASDAQ:NBTX)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 10, 2024 | globenewswire.comCenters for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025July 3, 2024 | benzinga.comThis Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For WednesdayMay 30, 2024 | globenewswire.comPacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare ConferenceMay 25, 2024 | finance.yahoo.comPacira BioSciences, Inc. (PCRX)May 10, 2024 | markets.businessinsider.comPacira BioSciences Announces Pricing Of $250 Mln Of Convertible Senior Notes, Due 2029July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 10, 2024 | finance.yahoo.comEarnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their ForecastsMay 10, 2024 | globenewswire.comPacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029May 8, 2024 | globenewswire.comPacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesMay 8, 2024 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comPacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...May 7, 2024 | investorplace.comPCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comPacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | msn.comPacira BioSciences Non-GAAP EPS of $0.62, revenue of $167.11MMay 7, 2024 | finance.yahoo.comPacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...See More Headlines Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Confirmed)7/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees711Year FoundedN/APrice Target and Rating Average Stock Price Target$43.60 High Stock Price Target$57.00 Low Stock Price Target$25.00 Potential Upside/Downside+117.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$1.43 Trailing P/E Ratio14.02 Forward P/E Ratio9.41 P/E GrowthN/ANet Income$41.96 million Net Margins10.34% Pretax Margin14.93% Return on Equity12.98% Return on Assets7.08% Debt Debt-to-Equity Ratio0.57 Current Ratio5.81 Quick Ratio4.78 Sales & Book Value Annual Sales$674.98 million Price / Sales1.38 Cash Flow$3.92 per share Price / Cash Flow5.12 Book Value$18.74 per share Price / Book1.07Miscellaneous Outstanding Shares46,550,000Free Float43,567,000Market Cap$933.33 million OptionableOptionable Beta0.88 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Charles A. Reinhart III (Age 63)C.P.A., M.B.A., Chief Financial Officer Comp: $780.58kMr. Daryl Gaugler (Age 62)Chief Operating Officer Comp: $778.77kMs. Kristen Williams J.D. (Age 50)Chief Administrative Officer & Secretary Comp: $799.63kMr. Anthony Molloy III (Age 50)Esq., Chief Legal & Compliance Officer Comp: $581.41kMr. David M. Stack (Age 74)Advisor Comp: $1.54MMr. Frank D. Lee (Age 56)CEO & Director Ms. Lauren Bullaro Riker (Age 45)Principal Accounting Officer & Senior VP of Finance Comp: $288.81kSusan MescoHead of Investor RelationsMr. Richard KahrVice President of Human ResourcesDr. Jonathan Slonin M.D. (Age 49)Chief Medical Officer Comp: $815.25kMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKAtea PharmaceuticalsNASDAQ:AVIRADC TherapeuticsNYSE:ADCTSeres TherapeuticsNASDAQ:MCRBCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 2,141 shares on 7/26/2024Ownership: 0.859%Legato Capital Management LLCBought 22,497 shares on 7/26/2024Ownership: 0.114%Allspring Global Investments Holdings LLCSold 3,504 shares on 7/26/2024Ownership: 0.014%Baillie Gifford & Co.Sold 194,677 shares on 7/25/2024Ownership: 1.732%Easterly Investment Partners LLCBought 26,235 shares on 7/25/2024Ownership: 0.227%View All Insider TransactionsView All Institutional Transactions PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 40.6% and is now trading at $20.03. View the best growth stocks for 2024 here. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Tuesday, May, 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by $0.04. The business had revenue of $167.12 million for the quarter, compared to analysts' expectations of $165.43 million. Pacira BioSciences had a net margin of 10.34% and a trailing twelve-month return on equity of 12.98%. What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Pacira BioSciences' major shareholders? Top institutional shareholders of Pacira BioSciences include Baillie Gifford & Co. (1.73%), Bank of New York Mellon Corp (0.86%), Nicholas Company Inc. (0.36%) and Gradient Investments LLC (0.34%). Insiders that own company stock include David M Stack, Daryl Gaugler, Kristen Williams, Jonathan Slonin, Roy Winston, Lauren Riker, Charles A Reinhart III, Max Reinhardt, Charles Anthony Laranjeira, Kristen Marie Williams, Lauren Bullaro Riker, Anthony Molloy, Mark A Kronenfeld, Mark Froimson and John P Phd Longenecker. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV) and Pfizer (PFE). This page (NASDAQ:PCRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
